Navigation Links
Inverness Medical Innovations Announces Second Quarter 2008 Results
Date:7/29/2008

on expense of $55.0 million and $10.1 million in the second

quarter of 2008 and 2007 GAAP results, respectively, including $11.7

million and $3.3 million charged to cost of sales, $1.0 million and $0.7

million charged to research and development and $42.1 million and $6.0

million charged to selling, general and administrative, in the respective

quarters, with $0.2 million and $0.1 million charged through equity

earnings of unconsolidated entities, net of tax during the respective

quarters.

(c) Restructuring charges associated with the decision to close facilities

of $23.6 million and $0.4 million for the second quarter of 2008 and 2007

GAAP results, respectively. The $23.6 million charge for the three months

ended June 30, 2008 included $4.8 million charged to cost of sales, $3.2

million charged to research and development, $3.0 million charged to

selling, general and administrative, $6.6 million charged to interest

expense and $6.0 million charged through equity earnings of unconsolidated

entities, net of tax. The $0.4 million charge for the second quarter of

2007 was charged to selling, general and administrative. These charges

have been excluded from net income or loss because they have a significant

impact on results yet do not occur on a consistent or regular basis in the

Company's business.

(d) Compensation costs of $7.2 million and $47.3 million associated with

stock-based compensation expense for the second quarter of 2008 and 2007

GAAP results, respectively, including $0.4 million and $0.1 million

charged to cost of sales, $1.1 million and $0.5 million charged to

research and development and $5.7 million and $46.7 million charged to

selling, general and administrative, in the respective quarters. The

$46.7 million charged to selling, general and administrative during the

2007 quarter include
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... ... launch of FireflySci Inc. (FFS) in early 2015, the company continues to shake up the ... Fonz in a lab coat and Large Marge have been posted on the company’s Facebook ... FireflySci is proud to be the only cuvette manufacturer is the world that has an ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today ... study of BHV-0223, a glutamate modulating agent. Biohaven ... and recently obtained clearance from the U.S. Food ... testing. Portage holds 54% equity interest in Biohaven, ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience International ... of the Japan Society of HTLV-1, held this week ... The purpose of the Society is to promote research ... development of medical technology and research related to these ... "HUYA is proud to support this prestigious ...
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... BioStorage Technologies, Inc.,(BST) will serve as the biorepository ... Study, a new landmark longitudinal study of coronary ... of Indianapolis and surrounding areas as study participants ... drugs and diagnostics that allow,doctors to better manage ...
... 23 Tengion Inc., a clinical,stage biotechnology company focused ... it has appointed Mark Stejbach as Vice,President, Marketing and ... marketing, sales, finance, and managed care experience from,both Merck ... very pleased to welcome Mark to the Tengion executive ...
... Delivers Solid Financial Performance While Building for the Future, ... GENZ ) today reported strong sales and profit growth ... commercial and clinical,programs., Revenue increased 25 percent to ... quarter. The increase was driven by,growth across all areas ...
Cached Biology Technology:BioStorage Technologies Serves as Repository for Landmark Study of Coronary Artery Disease 2Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning 2Genzyme Reports Strong Second-Quarter Growth 2Genzyme Reports Strong Second-Quarter Growth 3Genzyme Reports Strong Second-Quarter Growth 4Genzyme Reports Strong Second-Quarter Growth 5Genzyme Reports Strong Second-Quarter Growth 6Genzyme Reports Strong Second-Quarter Growth 7Genzyme Reports Strong Second-Quarter Growth 8Genzyme Reports Strong Second-Quarter Growth 9Genzyme Reports Strong Second-Quarter Growth 10Genzyme Reports Strong Second-Quarter Growth 11Genzyme Reports Strong Second-Quarter Growth 12Genzyme Reports Strong Second-Quarter Growth 13Genzyme Reports Strong Second-Quarter Growth 14Genzyme Reports Strong Second-Quarter Growth 15Genzyme Reports Strong Second-Quarter Growth 16Genzyme Reports Strong Second-Quarter Growth 17
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/5/2015)... The biosensors market is proving highly attractive ... newer sectors, and development of devices resulting in higher ... seen the entry of multiple participants each year with ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) Recent ... Global Biosensors Market ( http://www.frost.com/nee9 ), finds that ...
(Date:8/3/2015)... Synaptics, Inc. (Nasdaq: SYNA ), the ... members of the executive management team will present to ... Leadership Forum on Tuesday, August 11, 2015 at 1:00 ... the Sonnenalp Resort in Vail, CO. ... information. An audio webcast of the event will be ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... at the University of Rochester have found that small-bodied ... anti-cancer mechanism that appears to be different from any ... The findings are published in today,s issue of ... cancer in humans because many human cancers originate from ...
... Song-Charng Kong,s Iowa State University laboratory have come a ... combustion engine in 1879. There are fuel injectors ... efficiency, cleaner burning and greater reliability. But ... and all kinds of sensors recording engine cylinder pressure, ...
... for years about why uranium contamination in groundwater continues ... at the south end of the Hanford Site. The ... persists. Now, an innovative system has been ... site and to support future cleanup decisions. The site ...
Cached Biology News:Novel anti-cancer mechanism found in long-lived rodents 2Iowa State engineer works to clean and improve engine performance 2Sophisticated monitoring array to address mystery of uranium plume 2Sophisticated monitoring array to address mystery of uranium plume 3
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
Silica bead method is an economic method of DNA extraction from agarose...
DTT, 25g...
... overlays are commonly used in ... "DNA grade" agaroses either contain ... insect cells or lack the ... good overlays. Novagen's BacPlaque Agarose ...
Biology Products: